Cyclooxygenase-2 Inhibition Blocks M2 Macrophage Differentiation and Suppresses Metastasis in Murine Breast Cancer Model

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 May 14

PMID 23667623

Citations 92

Authors

Yi-Rang Na

Yi-Na Yoon

Da-In Son

Seung-Hyeok Seok

Affiliations

Soon will be listed here.

Abstract

Tumor cells are often associated with abundant macrophages that resemble the alternatively activated M2 subset. Tumor-associated macrophages (TAMs) inhibit anti-tumor immune responses and promote metastasis. Cyclooxygenase-2 (COX-2) inhibition is known to prevent breast cancer metastasis. This study hypothesized that COX-2 inhibition affects TAM characteristics potentially relevant to tumor cell metastasis. We found that the specific COX-2 inhibitor, etodolac, inhibited human M2 macrophage differentiation, as determined by decreased CD14 and CD163 expressions and increased TNFα production. Several key metastasis-related mediators, such as vascular endothelial growth factor-A, vascular endothelial growth factor-C, and matrix metalloproteinase-9, were inhibited in the presence of etodolac as compared to untreated M2 macrophages. Murine bone marrow derived M2 macrophages also showed enhanced surface MHCII IA/IE and CD80, CD86 expressions together with enhanced TNFα expressions with etodolac treatment during differentiation. Using a BALB/c breast cancer model, we found that etodolac significantly reduced lung metastasis, possibly due to macrophages expressing increased IA/IE and TNFα, but decreased M2 macrophage-related genes expressions (Ym1, TGFβ). In conclusion, COX-2 inhibition caused loss of the M2 macrophage characteristics of TAMs and may assist prevention of breast cancer metastasis.

Citing Articles

Radiation-induced rescue effect on human breast carcinoma cells is regulated by macrophages.

Pathikonda S, Tian L, Arava C, Cheng S, Lam Y Biochem Biophys Rep. 2025; 41:101936.

PMID: 40007574 PMC: 11850746. DOI: 10.1016/j.bbrep.2025.101936.

Understanding the role of TNFR2 signaling in the tumor microenvironment of breast cancer.

Mussa A, Ismail N, Hamid M, Al-Hatamleh M, Bragoli A, Hajissa K J Exp Clin Cancer Res. 2024; 43(1):312.

PMID: 39609700 PMC: 11603874. DOI: 10.1186/s13046-024-03218-1.

YIGSR, A Laminin-Derived Peptide, Dictates a Concentration-Dependent Impact on Macrophage Phenotype Response.

Jha A, Moore E Cell Mol Bioeng. 2024; 17(5):423-440.

PMID: 39513005 PMC: 11538123. DOI: 10.1007/s12195-024-00810-5.

Metabolic abnormalities in the bone marrow cells of young offspring born to mothers with obesity.

Phillips E, Alharithi Y, Kadam L, Coussens L, Kumar S, Maloyan A Int J Obes (Lond). 2024; 48(11):1542-1551.

PMID: 38937647 DOI: 10.1038/s41366-024-01563-x.

Decoding the complexity of delayed wound healing following infection.

Celik C, Lee S, Tanoto F, Veleba M, Kline K, Thibault G Elife. 2024; 13.

PMID: 38767331 PMC: 11105157. DOI: 10.7554/eLife.95113.

References

Lin E, Nguyen A, Russell R, Pollard J . Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med. 2001; 193(6):727-40. PMC: 2193412. DOI: 10.1084/jem.193.6.727. View

Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois R . Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998; 93(5):705-16. DOI: 10.1016/s0092-8674(00)81433-6. View

Leidi M, Gotti E, Bologna L, Miranda E, Rimoldi M, Sica A . M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J Immunol. 2009; 182(7):4415-22. DOI: 10.4049/jimmunol.0713732. View

Gilroy D, Colville-Nash P, Willis D, Chivers J, Paul-Clark M, Willoughby D . Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med. 1999; 5(6):698-701. DOI: 10.1038/9550. View

Bingle L, Brown N, Lewis C . The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002; 196(3):254-65. DOI: 10.1002/path.1027. View

Hassanzadeh Ghassabeh G, De Baetselier P, Brys L, Noel W, Van Ginderachter J, Meerschaut S . Identification of a common gene signature for type II cytokine-associated myeloid cells elicited in vivo in different pathologic conditions. Blood. 2006; 108(2):575-83. DOI: 10.1182/blood-2005-04-1485. View

Nakanishi Y, Nakatsuji M, Seno H, Ishizu S, Akitake-Kawano R, Kanda K . COX-2 inhibition alters the phenotype of tumor-associated macrophages from M2 to M1 in ApcMin/+ mouse polyps. Carcinogenesis. 2011; 32(9):1333-9. DOI: 10.1093/carcin/bgr128. View

Meng Y, Beckett M, Liang H, Mauceri H, van Rooijen N, Cohen K . Blockade of tumor necrosis factor alpha signaling in tumor-associated macrophages as a radiosensitizing strategy. Cancer Res. 2010; 70(4):1534-43. PMC: 8849568. DOI: 10.1158/0008-5472.CAN-09-2995. View

Sinha P, Clements V, Bunt S, Albelda S, Ostrand-Rosenberg S . Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol. 2007; 179(2):977-83. DOI: 10.4049/jimmunol.179.2.977. View

10.

Solinas G, Schiarea S, Liguori M, Fabbri M, Pesce S, Zammataro L . Tumor-conditioned macrophages secrete migration-stimulating factor: a new marker for M2-polarization, influencing tumor cell motility. J Immunol. 2010; 185(1):642-52. DOI: 10.4049/jimmunol.1000413. View

11.

Mantovani A, Sica A . Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol. 2010; 22(2):231-7. DOI: 10.1016/j.coi.2010.01.009. View

12.

Hallam S, Escorcio-Correia M, Soper R, Schultheiss A, Hagemann T . Activated macrophages in the tumour microenvironment-dancing to the tune of TLR and NF-kappaB. J Pathol. 2009; 219(2):143-52. PMC: 2935674. DOI: 10.1002/path.2602. View

13.

Iwata C, Kano M, Komuro A, Oka M, Kiyono K, Johansson E . Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis. Cancer Res. 2007; 67(21):10181-9. DOI: 10.1158/0008-5472.CAN-07-2366. View

14.

Kim E, Surh Y . 15-deoxy-Delta12,14-prostaglandin J2 as a potential endogenous regulator of redox-sensitive transcription factors. Biochem Pharmacol. 2006; 72(11):1516-28. DOI: 10.1016/j.bcp.2006.07.030. View

15.

Beatty G, Chiorean E, Fishman M, Saboury B, Teitelbaum U, Sun W . CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011; 331(6024):1612-6. PMC: 3406187. DOI: 10.1126/science.1198443. View

16.

Sinha P, Clements V, Fulton A, Ostrand-Rosenberg S . Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 2007; 67(9):4507-13. DOI: 10.1158/0008-5472.CAN-06-4174. View

17.

Zhang W, Xu W, Xiong S . Macrophage differentiation and polarization via phosphatidylinositol 3-kinase/Akt-ERK signaling pathway conferred by serum amyloid P component. J Immunol. 2011; 187(4):1764-77. DOI: 10.4049/jimmunol.1002315. View

18.

DeNardo D, Barreto J, Andreu P, Vasquez L, Tawfik D, Kolhatkar N . CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell. 2009; 16(2):91-102. PMC: 2778576. DOI: 10.1016/j.ccr.2009.06.018. View

19.

Pollard J . Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol. 2008; 84(3):623-30. PMC: 2516896. DOI: 10.1189/jlb.1107762. View

20.

Murdoch C, Tazzyman S, Webster S, Lewis C . Expression of Tie-2 by human monocytes and their responses to angiopoietin-2. J Immunol. 2007; 178(11):7405-11. DOI: 10.4049/jimmunol.178.11.7405. View